Safety and Effectiveness of Regorafenib in Routine Clinical Practice Settings

Trial Profile

Safety and Effectiveness of Regorafenib in Routine Clinical Practice Settings

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs Regorafenib (Primary)
  • Indications Colorectal cancer
  • Focus Adverse reactions
  • Acronyms Correlate
  • Sponsors Bayer
  • Most Recent Events

    • 25 Jul 2017 Status changed from recruiting to active, no longer recruiting.
    • 06 Jun 2017 Interim results (n=474) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 21 Jan 2017 Results of interim analysis of CORRELATE trial presented at the 2017 Gastrointestinal Cancers Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top